Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2011 June;63(3) > Minerva Ginecologica 2011 June;63(3):287-97

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

  NEW INSIGHTS INTO GYNECOLOGY IN 2011


Minerva Ginecologica 2011 June;63(3):287-97

language: English

Role of chemotherapy in epithelial ovarian cancer

Markman M.

Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia, PA, USA


PDF  


Despite the fact the standard-of-care primary chemotherapy strategy in epithelial ovarian cancer has undergone very limited changes over the past decade there have been important advances in treatment outcomes resulting from data generated in evidence-based trials that has modified the paradigm for second-line disease management. Recently reported data suggest novel classes of agents, including anti-angiogenic drugs and PARP inhibitors may add to the established utility of standard cytotoxic chemotherapy.

top of page

Publication History

Cite this article as

Corresponding author e-mail

maurie.markman@ctca-hope.com